RCUS
Price
$9.97
Change
+$0.34 (+3.53%)
Updated
Jun 6 closing price
Capitalization
1.02B
53 days until earnings call
XOMA
Price
$25.25
Change
+$0.25 (+1.00%)
Updated
Jun 6 closing price
Capitalization
296.3M
59 days until earnings call
Interact to see
Advertisement

RCUS vs XOMA

Header iconRCUS vs XOMA Comparison
Open Charts RCUS vs XOMABanner chart's image
Arcus Biosciences
Price$9.97
Change+$0.34 (+3.53%)
Volume$843.75K
Capitalization1.02B
XOMA Royalty
Price$25.25
Change+$0.25 (+1.00%)
Volume$34.43K
Capitalization296.3M
RCUS vs XOMA Comparison Chart
Loading...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCUS vs. XOMA commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a StrongBuy and XOMA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (RCUS: $9.13 vs. XOMA: $25.15)
Brand notoriety: RCUS and XOMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 64% vs. XOMA: 62%
Market capitalization -- RCUS: $1.02B vs. XOMA: $296.3M
RCUS [@Biotechnology] is valued at $1.02B. XOMA’s [@Biotechnology] market capitalization is $296.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileXOMA’s FA Score has 1 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • XOMA’s FA Score: 1 green, 4 red.
According to our system of comparison, XOMA is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 5 TA indicator(s) are bullish while XOMA’s TA Score has 4 bullish TA indicator(s).

  • RCUS’s TA Score: 5 bullish, 3 bearish.
  • XOMA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than XOMA.

Price Growth

RCUS (@Biotechnology) experienced а +6.04% price change this week, while XOMA (@Biotechnology) price change was +0.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

RCUS is expected to report earnings on Jul 31, 2025.

XOMA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.02B) has a higher market cap than XOMA($296M). XOMA YTD gains are higher at: -4.300 vs. RCUS (-38.684). XOMA has higher annual earnings (EBITDA): -5.42M vs. RCUS (-269M). RCUS has more cash in the bank: 978M vs. XOMA (105M). RCUS has less debt than XOMA: RCUS (60M) vs XOMA (119M). RCUS has higher revenues than XOMA: RCUS (258M) vs XOMA (10.2M).
RCUSXOMARCUS / XOMA
Capitalization1.02B296M345%
EBITDA-269M-5.42M4,960%
Gain YTD-38.684-4.300900%
P/E RatioN/AN/A-
Revenue258M10.2M2,529%
Total Cash978M105M931%
Total Debt60M119M50%
FUNDAMENTALS RATINGS
RCUS vs XOMA: Fundamental Ratings
RCUS
XOMA
OUTLOOK RATING
1..100
878
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
6357
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XOMA's Valuation (2) in the Biotechnology industry is somewhat better than the same rating for RCUS (54) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew somewhat faster than RCUS’s over the last 12 months.

XOMA's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

XOMA's SMR Rating (95) in the Biotechnology industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

XOMA's Price Growth Rating (57) in the Biotechnology industry is in the same range as RCUS (63) in the Pharmaceuticals Major industry. This means that XOMA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as XOMA (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to XOMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSXOMA
RSI
ODDS (%)
N/A
Bearish Trend 12 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
84%
Bullish Trend 12 days ago
90%
Momentum
ODDS (%)
Bullish Trend 12 days ago
79%
Bearish Trend 12 days ago
78%
MACD
ODDS (%)
N/A
Bearish Trend 12 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
76%
Bearish Trend 12 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
75%
Bullish Trend 12 days ago
80%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 26 days ago
83%
Bearish Trend 18 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
85%
Aroon
ODDS (%)
Bullish Trend 12 days ago
85%
Bullish Trend 12 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XOMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+1.11%
ACLX - RCUS
47%
Loosely correlated
-1.29%
APGE - RCUS
47%
Loosely correlated
-1.30%
XNCR - RCUS
47%
Loosely correlated
-2.58%
IMNM - RCUS
46%
Loosely correlated
+0.35%
TRDA - RCUS
45%
Loosely correlated
+0.91%
More

XOMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMA has been loosely correlated with GBIO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMA jumps, then GBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMA
1D Price
Change %
XOMA100%
+0.92%
GBIO - XOMA
39%
Loosely correlated
-1.11%
RCUS - XOMA
37%
Loosely correlated
+1.11%
LYEL - XOMA
37%
Loosely correlated
-0.15%
CRBU - XOMA
36%
Loosely correlated
+2.75%
NAUT - XOMA
35%
Loosely correlated
-3.95%
More